Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2070-2078

  Scagliotti, Giorgio V ^a   Krzakowski, Maciej ^b   Szczesna, Aleksandra ^c   Strausz, Janos ^d   Makhson, Anatoly ^g   Reck, Martin ⁱ   Wierzbicki, Rafal F ^l   Albert, Istvan ^e   Thomas, Michael ^j   Miziara, Jose Elias Abrao ^m   Papai, Zsolt S ^f   Karaseva, Nina ^h   Thongprasert, Sumitra ⁿ   Portulas, Elsa Dalmau ^o   Von Pawel, Joachim ^k   Zhang, Ke ^p   Selaru, Paulina ^p   Tye, Lesley ^p   Chao, Richard C ^p   Govindan, Ramaswamy ^q  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Regional Lung Diseases Hospital   (Poland)

^d NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^e Matrai Gyogyintezet ^*  (Hungary)

^f Fejer Megyei Szent Gyorgy Korhaz   (Hungary)

^g Moscow City Clinical Hospital of Oncology #62   (Russian Federation)

^h City Clinical Oncology Dispensary   (Russian Federation)

ⁱ KRANKENHAUS GROSSHANSDORF   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^l LAKERIDGE HEALTH CORPORATION   (Canada)

^m BARRETOS CANCER HOSPITAL   (Brazil)

ⁿ Faculty of Medicine Chiang Mai University   (Thailand)

^o HOSPITAL DE SABADELL   (Spain)

^p PFIZER INC   (United States)

^q WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; APPETITE; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DERMATITIS; DERMATITIS ACNEIFORM; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SMOKING; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PYRROLES; QUINAZOLINES; SMOKING; TREATMENT OUTCOME;

EID: 84863936062     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.2993     Document Type: Article

References (19)

1. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
2. Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006 (Pubitemid 44536887)
3. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003 (Pubitemid 36109749)
4. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003 (Pubitemid 36857948)
5. Novello S, Scagliotti GV, Rosell R, et al: Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced nonsmall cell lung cancer. Br J Cancer 101:1543-1548, 2009
6. Socinski MA, Novello S, Brahmer JR, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008 (Pubitemid 351264362)
7. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
10. EuroQol Group 2010: EQ-5D User Guide: Basic information on how to use EQ-5D, Version 3.0, April 2010
11. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progressionfree survival. J Natl Cancer Inst 101:1642-1649, 2009
12. Pickard AS, Neary MP, Cella D: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70, 2007
13. Johnson KR, Ringland C, Stokes BJ, et al: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 7:741-746, 2006 (Pubitemid 44283658)
14. Herbst RS, Ansari R, Bustin F, et al: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854, 2011
15. Miller VA, O'Connor P, Soh C, et al: A randomized, double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:407s, 2009 (suppl; abstr LBA8002)
16. Kabbinavar FF, Miller VA, Johnson BE, et al: Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28:544s, 2010 (suppl; abstr 7526)
17. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
18. Hershman JM, Liwanpo L: How does sunitinib cause hypothyroidism? Thyroid 20:243-244, 2010
19. Torino F, Corsello SM, Longo R, et al: Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228, 2009